Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases. Host: Amber BurgParticipants: David Hoelscher, Senior M...

In today’s episode, we delve into the fascinating world of Phase 1 clinical research at Fortrea’s Leeds Clinical Pharmacology Unit in the UK. We explore the operational challenges and innovative solutions behind a recent, complex ophthalmology ...

In this conversation today, we're going to dive into the evolving landscape of patient recruitment in ophthalmology and explore how Belite Bio and Fortrea are collaborating to overcome protocol complexities, and discuss the unique opportunities...

Join Leone Atkinson, Fortrea’s Executive Medical Director of Neuroscience and Ophthalmology, and Dr. John Huffaker from the Neuropsychiatric Research Center as they discuss the evolving landscape of Alzheimer’s clinical trials. Explore challeng...

In this episode we tackle one of the most critical aspects of these programs: long-term follow-up. Why is it so important? With CAR-T therapies, lentiviral vector-based treatments, and gene editing approaches requiring up to 15 years of follow-...

Expanding cell therapy beyond oncology opens new doors for patients—but it also introduces unique challenges in site identification and startup. From competing studies and resource limitations to regulatory nuances and cross-department collabor...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipant: Frederick DerosierDescription: Cell and gene therapy (CGT) trials are rewriting the rules of early-phase resear...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipants:  Andrea Seres, Senior Director of Strategic, Delivery and Growth in Oncology and Gene Therapy, FortreaMartin Co...

In this episode, host Laura Vidal, VP of Oncology at Fortrea, sits down with Dr. Ron Korn, Founder and Chief Medical Officer of Imaging Endpoints, to explore the evolving role of imaging in precision oncology. The conversation covers the latest...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipants:  Jan Skoumal, Head of Delivery for Oncology, Fortrea  Ludek Sojka, CEO, SCT BioDescription: ...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipant: Isabella Presch, Pediatric Clinical Research and Advanced TherapiesDescription: Today we're diving into one of ...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipant: Darby Thomas, Senior Scientific Director for Cell and Gene Therapies, Fortrea Description: In this first e...

Host: Dr. Mala Puri, Senior Medical Director at Fortrea Participant: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1DDescription: This episode brings together Mala Puri, Senior Medical D...

Host: Dr. Mala Puri, Senior Medical Director at Fortrea Participant: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1DDescription: This episode brings together Mala Puri, Senior Medical D...

Obesity is a serious, chronic disease with multiple health consequences. Effective treatment should go beyond simply reducing body weight. It must focus on decreasing fat mass, improving body composition including preserving muscle mass and enh...

Host: Dr. Friedrich Mittermayer, Sr. Medical Director for Endocrinology, FortreaParticipant: Dr. Esther Latres PhD, VP of Research at Breakthrough T1DDescription: This episode brings together Dr. Friedrich Mit...

In this episode, we hear from Sarah, a patient living with obesity and a passionate advocate, as she shares her personal experience participating in clinical trials. Sarah reflects on the emotional and practical motivations that drive patients ...

In this episode, we hear from Sarah, a patient living with obesity, as she shares her lifelong journey—from early body image struggles and restrictive dieting to participating in a televised weight-loss transformation. Despite achieving peak fi...

Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea Participants: Abby Fuller, Senior Director of Strategic Delivery Growth in Neuroscience, Fortrea Walter Gonz...

Host: Dr. Cheerag Shirodaria, VP and Cardiovascular/Metabolic Therapeutic Area Head, FortreaParticipant: Chris Farina, Abcentra CEO Description: In episode two, the conversation turns to clinical developm...

Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at FortreaParticipants:  Leone Atkinson, Executive Medical Director of Neuroscience and Ophthalmology at Fortrea Alicia Baker, Vice ...

Host: Dr. Cheerag Shirodaria, VP and Cardiovascular/Metabolic Therapeutic Area Head, FortreaParticipant: Chris Farina, Abcentra CEO Description: Despite advances in lipid-lowering and antithrombotic thera...

Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at FortreaParticipants:  Leone Atkinson, Executive Medical Director of Neuroscience and Ophthalmology, Fortrea Robin Wolz, Chief Sci...

Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at FortreaParticipants:  Joanie Brown, Head of Operations at our Rapid Development Studio AI/ML, Fortrea Mark Austin, CTO at Ixico&n...

In our third episode, we discuss collaboration between Contract Research Organizations and biotech companies, emphasizing the importance of communication and understanding in clinical trials.Our moderator, Dr. Ken Park, is joined by an e...